Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

14 API Suppliers, 1 USDMF, 1 EU WC, 2 NDC API, 13 Listed Suppliers, $ API Reference Price

14 API Suppliers
1 USDMF
1 EU WC
2 NDC API
13 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

11 Drugs in Development

11 Drugs in Development

INTERMEDIATES

15 Intermediates Suppliers

15 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

18 FDF Dossiers, 5 FDA Orange Book, 5 Europe, 6 Australia, 2 South Africa

18 FDF Dossiers
5 FDA Orange Book
5 Europe
6 Australia
2 South Africa

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 50MG BASE, CAPSULE;ORAL - EQ 75MG BASE

drugProductComposition
CAPSULE;ORAL - EQ 50MG BASE
CAPSULE;ORAL - EQ 75MG BASE

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 3 DKSH, 1 Faran Shimi Pharmaceutical, 6 Gangwal Healthcare, 1 ACG Worldwide, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 10 Corel Pharma Chem, 2 DFE Pharma, 6 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 15 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 8 Microlex e.U, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 1 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 9 Roquette, 6 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 2 The Dow Chemical Company, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

43 Coating Systems & Additives, 23 Fillers, Diluents & Binders, 20 Controlled & Modified Release, 14 Direct Compression, 12 Thickeners and Stabilizers, 11 Lubricants & Glidants, 8 Co-Processed Excipients, 7 Film Formers & Plasticizers, 7 Granulation, 6 Disintegrants & Superdisintegrants, 5 Empty Capsules, 4 Emulsifying Agents, 4 Vegetarian Capsules, 4 Taste Masking, 4 API Stability Enhancers, 4 Coloring Agents, 3 Chewable & Orodispersible Aids, 2 Rheology Modifiers, 1 Solubilizers

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 44 NEWS #PharmaBuzz

media
3 DATA COMPILATION #PharmaFlow
44 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

5 Finished Drug Prices, 10 Annual Reports

globalSalesInformation
5 Finished Drug Prices
10 Annual Reports

MARKET PLACE

3 APIs, 1 FDF Dossiers

marketPlace
3 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents, 28 US Exclusivities, 2 Health Canada Patents

patents
68 US Patents
28 US Exclusivities
2 Health Canada Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 78,477

MARKET PLACE

API

FDF

15INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

11DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

11,709

Finished Drug Prices

108 RELATED EXCIPIENT COMPANIES

182EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1195768-06-9, Dabrafenib (mesylate), Gsk 2118436b, Dabrafenib mesilate, Dabrafenib mesylate [usan], Unii-b6dc89i63e

Molecular Formula

C₂₄H₂₄F₃N₅O₅S₃

Molecular Weight

615.7 g/mol

InChI Key

YKGMKSIHIVVYKY-UHFFFAOYSA-N

FDA UNII

B6DC89I63E

Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.

1 2D Structure

Dabrafenib Mesylate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic acid

2.1.2 InChI

InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)

2.1.3 InChI Key

YKGMKSIHIVVYKY-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O

2.2 Other Identifiers

2.2.1 UNII

B6DC89I63E

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 1195768-06-9

2. Dabrafenib (mesylate)

3. Gsk 2118436b

4. Dabrafenib Mesilate

5. Dabrafenib Mesylate [usan]

6. Unii-b6dc89i63e

7. Gsk-2118436 Mesylate

8. Gsk-2118436b

9. Methane Sulfonate Salt

10. Gsk2118436b

11. Gsk2118436 Mesylate

12. B6dc89i63e

13. Chebi:75048

14. Gsk-2118436b Mesylate

15. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide Methanesulfonate

16. Gsk2118436b, Methane Sulfonate Salt

17. Gsk-2118436 Methanesulfonate Salt

18. Gsk-2118436b Methanesulfonate Salt

19. Gsk2118436 Mesylate;gsk 2118436b

20. Dabrafenib Mesilate (jan)

21. Dabrafenib Mesylate (gsk-2118436)

22. Dabrafenib Mesylate (usan)

23. Dabrafenib Mesilate [jan]

24. Taflinar

25. N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic Acid

26. Dabrafenib Methanesulfonate

27. Tafinlar (tn)

28. Gsk2118436 Methane Sulfonate Salt

29. Dabrafenib Monomesylate

30. Gsk 2118436 Mesylate

31. Schembl1127269

32. Chembl2105729

33. Dabrafenib Mesylate [mi]

34. Dtxsid70152500

35. Amy30045

36. Bcp04738

37. Ex-a1559

38. Dabrafenib Mesilate [who-dd]

39. Hy-14660a

40. Mfcd20922872

41. S5069

42. Akos025396661

43. Ccg-270246

44. Cs-1641

45. Dabrafenib Mesylate [orange Book]

46. Ac-31302

47. As-17010

48. Ft-0696677

49. D10104

50. A903491

51. Sr-01000941590

52. Sr-01000941590-1

53. Q27145089

54. Gsk2118436 Ms Salt, Dabrafenib Ms Salt, Gsk2118436a Ms Salt

55. Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)- 2-fluorophenyl)-2,6-difluoro-, Methanesulfonate (1:1)

56. Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, Methanesulfonate (1:1)

57. Dabrafenib Mesylaten-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide, Methanesulfonic Acid; Dabrafenib Mesylate

58. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl)-2,6- Difluorobenzenesulfonamide Monomethanesulfonate

59. N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate

60. N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate

2.3.2 Other Synonyms

1. 1195765-45-7

2. Dabrafenib

2.4 Create Date

2009-12-22

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₄F₃N₅O₅S₃
Molecular Weight	615.7 g/mol
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	14
Rotatable Bond Count	6
Exact Mass	615.08916689 g/mol
Monoisotopic Mass	615.08916689 g/mol
Topological Polar Surface Area	210 Å²
Heavy Atom Count	40
Formal Charge	0
Complexity	910
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

* Melanoma:

Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4. 4 and 5. 1).

* Adjuvant treatment of melanoma:

Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

* Non-small cell lung cancer (NSCLC):

Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.

Treatment of melanoma, Treatment of solid malignant tumours (excluding melanoma)

5 Pharmacology and Biochemistry

5.1 ATC Code

L01EC02

API SUPPLIERS

01

Fermion Oy

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

With Fermion, start the journey of your innovative API.

Contact Supplier

Finland

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

02

Jinan Tantu Chemicals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Contact Supplier

China

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

03

Sichuan Elixir Pharmaceuticals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..

Contact Supplier

China

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

04

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

05

Guangdong Raffles PharmaTech Co Lt...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

06

Guangdong Raffles PharmaTech Co Lt...

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

01

Jinan Tantu Chemicals

China

Medlab Asia & Asia Health

Not Confirmed

Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

2,6-Difluorobenzenesulfonyl chloride

CAS Number : 60230-36-6

End Use API : Dabrafenib Mesylate

02

Jinan Tantu Chemicals

China

Medlab Asia & Asia Health

Not Confirmed

Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Methyl 3-amino-2-fluorobenzoate

CAS Number : 1195768-18-3

End Use API : Dabrafenib Mesylate

03

Jinan Tantu Chemicals

China

Medlab Asia & Asia Health

Not Confirmed

Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

2-chloro-4-methylpyrimidine

CAS Number : 13036-57-2

End Use API : Dabrafenib Mesylate

04

Jinan Tantu Chemicals

China

Medlab Asia & Asia Health

Not Confirmed

Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

2,2-Dimethylthiopropionamide

CAS Number : 630-22-8

End Use API : Dabrafenib Mesylate

Portfolio PDF

Product Web Link

Virtual Booth

China

Medlab Asia & Asia Health

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Australia

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

South Africa

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE;ORAL - EQ 50MG BASE

USFDA APPLICATION NUMBER - 202806

DOSAGE - CAPSULE;ORAL - EQ 75MG BASE

USFDA APPLICATION NUMBER - 202806

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

Fillers, Diluents & Binders

Controlled & Modified Release

Direct Compression

Thickeners and Stabilizers

Lubricants & Glidants

Co-Processed Excipients

Film Formers & Plasticizers

Granulation

Disintegrants & Superdisintegrants

Empty Capsules

Emulsifying Agents

Vegetarian Capsules

Taste Masking

API Stability Enhancers

Coloring Agents

Chewable & Orodispersible Aids

Rheology Modifiers

Solubilizers

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

Finished Drug Prices

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF DOSSIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

01

NOVARTIS

DABRAFENIB MESYLATE

DABRAFENIB MESYLATE

DDL Conference

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Health Canada Patents

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Find Dabrafenib Mesylate manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

14 API Suppliers

1 USDMF

1 EU WC

2 NDC API

13 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

11 Drugs in Development

INTERMEDIATES

15 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

18 FDF Dossiers

5 FDA Orange Book

5 Europe

6 Australia

2 South Africa

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 50MG BASE

CAPSULE;ORAL - EQ 75MG BASE

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

3 DKSH

1 Faran Shimi Pharmaceutical

6 Gangwal Healthcare

1 ACG Worldwide

4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

10 Corel Pharma Chem

2 DFE Pharma

6 Gangwal Chemicals

5 Ideal Cures Pvt Ltd

15 Kerry

3 Kima Chemical

6 Lonza Capsugel

8 Microlex e.U

1 Novo Excipients

1 Pharmatrans-Sanaq

1 Pluviaendo

2 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

9 Roquette

6 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

8 Sigachi Industries

2 The Dow Chemical Company

2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

43 Coating Systems & Additives

23 Fillers, Diluents & Binders

20 Controlled & Modified Release

14 Direct Compression

12 Thickeners and Stabilizers

11 Lubricants & Glidants

8 Co-Processed Excipients

7 Film Formers & Plasticizers

7 Granulation

6 Disintegrants & Superdisintegrants

5 Empty Capsules

4 Emulsifying Agents

4 Vegetarian Capsules

4 Taste Masking

4 API Stability Enhancers

4 Coloring Agents

3 Chewable & Orodispersible Aids

2 Rheology Modifiers

1 Solubilizers

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow

44 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

5 Finished Drug Prices

10 Annual Reports

MARKET PLACE

3 APIs